T. Mansy

James Cook University Hospital — United Kingdom

Medicine · Health Sciences

10h-index636citations27works60.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(12), Occupational and environmental lung diseases(8), Cancer Immunotherapy and Biomarkers(7), Lung Cancer Diagnosis and Treatment(7), Pleural and Pulmonary Diseases(7)

Publications26 total

258 The Real-World Outcomes of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Retrospective Study
Lung Cancer·2026
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial
ESMO Open·2025· 12 citedOpen Access
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
The Lancet Respiratory Medicine·2024· 99 citedOpen Access
PR059/#861  From phenotype to genotype: peroperative prediction of HRD status in epithelial ovarian cancers (EOC) based on serum CA-125, intraoperative tumour characteristics and surgical resectability
2023Open Access
PL03.10 MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma
Journal of Thoracic Oncology·2023· 8 citedOpen Access
LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Annals of Oncology·2023· 4 citedOpen Access
MARS 2: Extended Pleurectomy Decortication and Chemotherapy for Pleural Mesothelioma
SSRN Electronic Journal·2023· 2 citedOpen Access
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology·2022· 112 citedOpen Access
108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Annals of Oncology·2022· 12 citedOpen Access
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom
BMC Cancer·2021· 29 citedOpen Access
Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United Kingdom
2020· 5 citedOpen Access
1379P Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom
Annals of Oncology·2020· 2 citedOpen Access
Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma
BMJ Open·2020· 80 citedOpen Access
Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC): real-world data from the United Kingdom
Lung Cancer·2020
A regional experience of advanced, non-squamous, ALK positive patients: their treatment and outcomes
Lung Cancer·2020
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
Journal of Clinical Oncology·2019· 65 citedOpen Access
The experience of immunotherapy in lung cancer: an audit of patients receiving first-line immunotherapy for metastatic small cell lung cancer in South Tees between June 2016 and December 2017
Lung Cancer·2019
The experience of immunotherapy in lung cancer: an audit of immunotherapy use as second-line treatment for metastatic non-small cell lung cancer (NSCLC) in the South Tees region
Lung Cancer·2019
OC-0537: Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: a phase III trial
Radiotherapy and Oncology·2018
Guillain–Barré‐like syndrome during pembrolizumab treatment
Muscle & Nerve·2018· 20 cited
page 1 of 2Next →

Frequent Co-authors

Corinne Faivre‐Finn(8), John Edwards(8), Robert C. Rintoul(8), Laura Cove-Smith(7), Paul Taylor(6), E. Aynsley(6), C. Peedell(6), Liz Darlison(5), Diego Cortinovis(4), Luis Enrique Chara Velarde(4), I. Diaz Perez(4), Eric Lim(4), David Waller(4), Manjusha Keni(4), Sanjay Popat(4), Nick Maskell(4), D. Muthukumar(4), Z. Tasigiannopoulos(4), Andrea Billè(4), Jonathan Shamash(4)